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Summary
Introduction: Proton-pump inhibitors (PPIs) are widely used drugs, though it should be noted that exces-
sive use is not in line with the accepted indications in Spain and throughout Europe. Furthermore, some
authors have established a possible PPI link to the risk of fracture. In this paper, we make an initial appro-
ach to knowledge into PPI consumption and analyze what indication is prescribed. We also studied the
drugs’ possible association with increased risk of fragility fracture in users. 
Material and method: An observational, transversal, open and descriptive study in which a number of
randomly-chosen patients were interviewed. These patients had been treated in outpatient, emergency
and primary care centers. Some had also been treated in hospital wards.
Results: Of the 411 patients interviewed, 54% received PPIs. The average age was 63.3 years, compared
with 46% that did not take them and who were younger presenting a mean age of 50.9 years. Gender
distribution was similar. PPIs were mainly used as a “gastric protector”, in 39.8% of the patients, with no
indication appearing in the technical specifications for this group of drugs. Consumers of PPIs presented
a higher prevalence of all fragility fractures.
Conclusions: More than half of the population surveyed consumed PPI. Of this group, about 40% did so
without proper medical advice. Therefore, in addition to the higher prevalence of fragility fractures that
suggest a possible increased risk of fracture among its users, we consider the need for a more rational
use of these drugs. These preliminary findings point to a need for further studies to confirm the relations-
hip between PPIs and the risk of osteoporotic fracture.
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Introduction
The proton-pump inhibitors (PPIs) are a group of
drugs whose main action is a prolonged decrease
in the stomach’s hydrochloric acid secretion1. They
are quite safe and widely used by the public, but
not without side effects2. It has been reported that
consumption of PPIs could be related to an incre-
ased risk of fragility fractures. There are published
studies in the literature that support this3-6 and
others that deny it7.
Moreover, PPIs have been used for many years
as a stomach protector that may be caused by
taking certain medications. This use is not stated
in the therapeutic indications registered by the
European Medicines Agency8 and summarized in
Table 1. There are no studies or scientific eviden-
ce to support its use for this purpose. Conversely,
administration of PPIs in conjunction with other
drugs may sometimes be counterproductive, as,
for example, calcium carbonate, which requires an
acid medium for optimal absorption9, absorption
would be inhibited, therefore, with simultaneous
administration of PPI.
We conducted a study in a group of patients
randomly recruited from different healthcare areas
of the Insular University Hospital of Las Palmas,
Spain, in order to collect initial data on the preva-
lence of PPI and the reasons why it is prescribed,
and to study the prevalence of fragility fractures in
these patients and possible links to PPI use.
Material and methods
To carry out this work, we designed a question-
naire composed of 10 items that were presented to
a group of 411 randomly-chosen patients of both
sexes. Those interviewed were treated in various
health centers: emergency department, hospital
internal medicine outpatient, primary care consul-
tation and patients admitted to hospital on the
wards. The minimum age for inclusion was 18
years, with no upper age limit. There was no choi-
ce in the type of patients in any working environ-
ment, whether in the hospital and health centers.
Five doctors participated in the data collection.
The questionnaire results were entered into a
database designed ad hoc and consisting of a total
of 20 items related, for the most part, to the use of
PPIs.
The statistical study consisted of a descriptive
analysis, using mean and standard deviation for
the quantitative variables and percentage for cate-
gorical variables. To compare categorical variable
tests Chi-square and Fisher were used. The
Student t-test or Mann-Whitney U test were used
to compare quantitative variables, depending on
whether or not the variables followed a normal
distribution. Variable normality was analyzed
using the Kolmogorov-Smirnov. All results were
adjusted for age. The significance level was set at
5% (p <0.05).
Results
Table 2 shows the characteristics of the patients
included in the study. A total of 411 patients were
interviewed, more than half (54%) were receiving
PPIs during the field-work survey period, while
46% did not take them. The average age of
patients receiving PPIs was greater than those not
receiving it (63.3 and 50.9 years, respectively). The
age range was 18 to 95 years. The gender distribu-
tion of patients in both groups showed no statisti-
cally significant differences.
Table 3 shows the indications for which
patients received PPIs. Overall, the most common
indication was as proton pump inhibitors, which
was obtained in about 40% of patients with hiatal
hernia as a second cause, which was found in 10%
of the users of PPIs. In this respect, no statistically
significant differences between men and women
were obtained.
The most commonly used PPIs were omepra-
zole (72.6%), followed by pantoprazole (13.4%).
The use of lansoprazole, esomeprazole, and
rabenprazol was more limited. The minimum
length of treatment with PPIs was 1 month, which
was observed in 8 cases, and the maximum 204
months, obtained in 2 patients.
Table 4 shows the prevalence of fragility frac-
tures in the participants. Patients taking PPIs at the
time of the survey had a higher prevalence of fra-
gility fractures than those not taking the drugs
(12.6% vs 2.6% respectively), with an OR of 5,284,
the difference being statistically significant. The
prevalence of all different types, vertebral, non-
vertebral and hip were higher in patients receiving
PPIs (p=0.003).
Discussion
Our study shows that there is a significant con-
sumption of PPIs among patients who may not be
prescribed them. In our series, 54.1% of patients
reported habitually taking PPIs at the time of the
survey, similar to the results described elsewhere.
In a population of elderly women in Australia, in
the so-called Australian Longitudinal Study on
Women's Health, with a sample size of 4,432
women, 52.5% received PPI4. In the hospital set-
ting, in a sample of 834 admitted patients, 58.7%
were taking PPIs, and "reviewing their indications"
they were correct in only 50.1% of the patients10.
In another study of hospitalized patients in a ward
of respiratory diseases, 44% were receiving PPIs,
of which 68% did not have a correct indication11.
By far the most common reason for PPI use in
our patients was as a stomach "protector" against
other drugs (almost 40% of the total). We would
point out that this indication does not exist in any
PPI specifications sheet8, and there are no studies
indicating that these drugs are effective for this.
However, there is a widespread notion in the
medical profession that it is prudent to administer
various drugs, even when they may be gastro-ero-
sive. The PPI should be added as a "protective"
effect only described as effective and indication in
the product information for these nonsteroidal
anti-inflammatory drugs8, and its usefulness is not
proven in patients receiving oral corticosteroids.
Furthermore, although PPIs are considered
109
ORIGINALS / Rev Osteoporos Metab Miner 2015 7;4:107-111
safe with few side effects, their use has been asso-
ciated with an increased prevalence of certain
diseases, and the risk of acute myocardial12, neph-
ritis or hypomagnesemia14 intersticial13. In the case
of bone metabolic disorder IBP consumption has
been associated with the presence of fractures in
young adults15, behaving as an independent risk
factor for the production of fractures, both as a dif-
ferent studies3-6,16 metaanalysis17 where an increa-
sed risk of vertebral, non-vertebral and hip fractu-
res, especially in the elderly was observed. This
has caused concern among health authorities who
have published several notices on this topic17-20.
Our results are indicative in this sense, not conclu-
sive, because, although the prevalence of fragility
fractures was much higher in the group that recei-
ved PPI, methodological factors discussed below
make us cautious when considering the real mea-
ning of these findings.
The study has several limitations. We do not
consider the co-morbidity of these patients.
Therefore, we cannot establish with certainty
which users of PPIs have a greater risk of fragility
fractures due to these drugs as with patients taking
the drugs there could probably be others receiving
drugs whose gastric effects were protected
(although incorrectly) that would produce increa-
sed bone fragility (as in the case of corticoste-
roids). Furthermore, taking these other drugs may
in turn indicate the existence of conditions that
damage the bone (for example, rheumatoid arthri-
tis). Another limitation is the small sample size. On
the other hand, this is only a preliminary study to
confirm the suspected overuse of PPIs, with an
indication that there is no clinical evidence of any
kind and that carries a huge unjustified economic
cost. We should keep in mind the possible side
effects described in other studies discussed above.
Regarding the economic costs, in 2014, more
than 3 million containers of PPI were sold in the
Canary Islands, which generated an expense of 20
million euros20, much of which, as we have just
shown, without a correct indication. This relates to
consumption financed by the Canary Island
Health Service. Actual consumption may be much
higher, because PPIs are dispensed without a
prescription.
In conclusion, although these results are preli-
minary and include a small sample size, our study
shows that more than half of the patients receiving
PPIs and, of these, almost 40% take it with an indi-
cation which is not approved, which could, in
addition to a significant unnecessary health spen-
ding, generate an increased risk of other diseases,
including fragility fractures. Therefore, we recom-
mend more in depth, broader studies in this direc-
tion.
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Table 2. Characteristics of patients included in the study, depending on the no decision or PPI
Table 3. Indication for receiving PPI*
Table 4. Presence of fragility fractures and current use of PPIs
They take PPI Do not take PPI Value of p
Patients, n (%) 223 (54.1%) 188 (45.9%)
Age (years), mean ± SD 63.3±13.7 50.9±17.5 0.001
Sex, n (%)
men 98 (53.6%) 85 (46.4%)
p=0.843
women 125 (54.6%) 104 (45.4%)
SD: standard deviation.
*: data calculated only in the subgroup taking the drug at the time of the survey.
Indication Total Men Women Value of p
Hiatal hernia 41 (10%) 15 (8.2%) 26 (11.4%) 0.288
Gastroesophageal reflux 32 (7.8%) 13 (7.1%) 19 (8.3%) 0.653
Peptic ulcer  19 (4.6%) 10 (5.5%) 9 (3.9%) 0.461
Helicobacter 5 (1.2%) 2 (1.1%) 3 (1.3%) 0.841
Gastric protector 164 (39.8%) 69 (37.7%) 95 (41.5%) 0.436
Brittle fracture They take PPI Do not take PPI Value of p OR (IC 95%)
Yes 28 (12.6%) 5 (2.6%)
0.001
5.284
(1.998;13.976)No 195 (87.4%) 184 (97.4%)
Kind
fracture
Vertebral 14 (6,3%) 4 (2.1%)
0.003No vertebral 6 (2.7%) 1 (0.5%)
Hip 7 (3.1%) 0 (0%)
